Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis

Ticker
ROVI.MC

Price
73.60
Stock movement up
+1.45 (2.01%)
Company name
Laboratorios Farmaceuticos ROVI
Exchange
(MC
,
Currency
EUR
)
Sector
Healthcare >
Drug Manufacturers - Specialty & Generic
Market cap
3.76B
Ent value
4.00B
Price/Sales
5.20
Price/Book
5.95
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
31.07
Forward P/E
23.55
PEG
-
EPS growth
30.36%
1 year return (CAGR)
16.64%
3 year return (CAGR)
22.78%
5 year return (CAGR)
10.10%
10 year return (CAGR)
17.85%
Last updated: 2026-02-12

DIVIDENDS

ROVI.MC does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E31.07
Price to OCF21.63
Price to FCF35.12
Price to EBITDA35.48
EV to EBITDA37.74

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales5.20
Price to Book5.95
EV to Sales5.53

FINANCIALS

Per share

Loading...
Per share data
Current share count51.15M
EPS (TTM)2.37
FCF per share (TTM)2.10

Income statement

Loading...
Income statement data
Revenue (TTM)724.20M
Gross profit (TTM)625.86M
Operating income (TTM)160.20M
Net income (TTM)121.15M
EPS (TTM)2.37
EPS (1y forward)3.13

Margins

Loading...
Margins data
Gross margin (TTM)86.42%
Operating margin (TTM)22.12%
Profit margin (TTM)16.73%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash49.25M
Net receivables191.39M
Total current assets559.19M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets922.07M
Accounts payable102.22M
Short/Current long term debt123.62M
Total current liabilities185.42M
Total liabilities289.27M
Shareholder's equity632.80M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)174.04M
Capital expenditures (TTM)66.85M
Free cash flow (TTM)107.19M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity19.15%
Return on Assets13.14%
Return on Invested Capital19.15%
Cash Return on Invested Capital16.94%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open73.00
Daily high74.00
Daily low72.95
Daily Volume205K
All-time high91.50
1y analyst estimate80.96
Beta0.20
EPS (TTM)2.37
Dividend per share0.00
Ex-div date14 Jul 2025
Next earnings date25 Feb 2026

Downside potential

Loading...
Downside potential data
ROVI.MCS&P500
Current price drop from All-time high-19.56%-0.89%
Highest price drop-67.18%-56.47%
Date of highest drop6 Mar 20099 Mar 2009
Avg drop from high-25.69%-10.86%
Avg time to new high29 days12 days
Max time to new high1773 days1805 days
COMPANY DETAILS
ROVI.MC (Laboratorios Farmaceuticos ROVI) company logo
Marketcap
3.76B
Marketcap category
Mid-cap
Description
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, aseptic filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
Employees
2197
Investor relations
-
CEO
Country
Spain
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
As the pan-European STOXX Europe 600 Index reaches new intraday highs, optimism about the eurozone economy is helping to counteract recent market volatility. In this environment, identifying undervalu...
February 11, 2026
Amid optimism about the European economy and favorable interest rate conditions, major stock indexes across the region have experienced gains, with Germany's DAX and France's CAC 40 Index showing nota...
January 13, 2026
As of December 2025, the European stock market has shown mixed performance, with indices like Germany's DAX seeing gains while others such as France's CAC 40 have experienced declines. Amidst potentia...
December 15, 2025
In November 2025, global markets are grappling with a complex mix of factors, including record-low U.S. consumer sentiment and a prolonged government shutdown impacting investor confidence. Amidst the...
November 14, 2025
Amid recent profit-taking and political uncertainties, the European markets have seen a slight downturn, with the STOXX Europe 600 Index dropping 1.10% from its record highs. Despite these challenges,...
October 16, 2025
As the European markets grapple with concerns about global growth following weak U.S. jobs data and a stronger euro, the pan-European STOXX Europe 600 Index recently ended slightly lower. In this cont...
September 11, 2025
As the European market experiences a positive surge, with the STOXX Europe 600 Index climbing 2.11% on strong corporate earnings and hopes for geopolitical resolutions, investors are increasingly atte...
August 13, 2025
As the European market navigates a landscape marked by tentative optimism surrounding potential EU-U.S. trade agreements, indices like the STOXX Europe 600 have experienced modest gains, reflecting ca...
July 31, 2025
As European markets experience tentative optimism amid potential trade agreements with the U.S., the pan-European STOXX Europe 600 Index has seen a modest rise. In this environment, identifying stocks...
July 31, 2025
As the European market navigates a landscape marked by cautious optimism surrounding potential EU-U.S. trade agreements, the pan-European STOXX Europe 600 Index has shown modest gains. With the Europe...
July 30, 2025
Next page